MOWI ASA financials
MOWI ASA
Country: NO Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
549300W1OGQF5LZIH349 Financial statements
(EUR, as reported — unscaled; 98 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Other income | €37.4M | €27.5M |
| Employee benefits expense | €705.5M | €647.9M |
| Raw materials & consumables used | €2.80B | €2.74B |
| Depreciation & amortisation | €447.8M | €403.8M |
| Profit before tax | €631.7M | €898.7M |
| Income tax expense | €156.9M | €459.2M |
| Profit for the year | €474.8M | €439.5M |
| — attributable to owners | €468.5M | €444.4M |
| — attributable to NCI | €6.3M | -€4.9M |
| Total comprehensive income | €540.6M | €392.6M |
| Per share | ||
| Basic EPS | €0.91 | €0.86 |
| Diluted EPS | €0.91 | €0.86 |
| Free cash flow / share | €1.04 | €1.17 |
| Cash flow statement | ||
| Net cash from operating activities | €916.6M | €992.2M |
| Net cash from investing activities | -€332.1M | -€413.6M |
| Net cash from financing activities | -€598.3M | -€458.2M |
| Dividends paid | €293.5M | €326.1M |
| Lease liability payments | €221.2M | €196.2M |
| Balance sheet | ||
| Total assets | €8.55B | €8.24B |
| Non-current assets | €4.44B | €4.26B |
| Property, plant & equipment | €1.98B | €1.88B |
| Right-of-use assets | €524.9M | €470.1M |
| Intangible assets & goodwill | €369.6M | €368.1M |
| Current assets | €4.11B | €3.98B |
| Inventories | €587.3M | €605.1M |
| Trade & other receivables | €661.5M | €654.3M |
| Cash & equivalents | €276.7M | €288.4M |
| Total equity | €4.01B | €3.75B |
| — attributable to owners | €3.84B | €3.59B |
| Non-controlling interests | €166.4M | €161.4M |
| Non-current liabilities | €3.14B | €3.22B |
| Long-term borrowings | €1.96B | €2.09B |
| Lease liabilities (non-current) | €338.4M | €299.3M |
| Current liabilities | €1.41B | €1.26B |
| Current portion of long-term borrowings | €200.0M | €100.0K |
| Lease liabilities (current) | €179.4M | €174.5M |
| Deferred tax liabilities | €834.4M | €820.4M |
| Derived metrics | ||
| Free cash flow | €542.4M | €595.9M |
| Net margin | 8.5% | 8.0% |
| Return on equity | 11.9% | 11.7% |
| Cash conversion ratio | 1.93× | 2.26× |
| Capex coverage | 2.45× | 2.50× |
| Other reported items | ||
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €514.0M | €427.4M |
| Adjustments For Fair Value Gains Losses | -€68.3M | -€20.3M |
| Adjustments For Finance Income Cost | €7.6M | -€5.1M |
| Adjustments For Interest Expense | €143.5M | €113.1M |
| Adjustments For Provisions | €800.0K | -€2.6M |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | €29.5M | €28.4M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -€9.0M | -€35.9M |
| Balances With Banks | €276.7M | €288.4M |
| Basic Earnings Loss Per Share From Continuing Operations | €0.91 | €0.86 |
| Comprehensive Income Attributable To Noncontrolling Interests | €6.3M | -€17.4M |
| Comprehensive Income Attributable To Owners of Parent | €534.3M | €410.0M |
| Current Biological Assets | €2.31B | €2.14B |
| Current Provisions | €16.6M | €44.8M |
| Current Restricted Cash and Cash Equivalents | €13.5M | €14.5M |
| Current Tax Liabilities | €141.2M | €184.4M |
| Deferred Tax Assets | €87.6M | €76.0M |
| Diluted Earnings Loss Per Share From Continuing Operations | €0.91 | €0.86 |
| Dividends Received Classified As Investing Activities | €24.4M | €18.7M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €2.2M | -€2.8M |
| Equity and Liabilities | €8.55B | €8.24B |
| Expense of Restructuring Activities | €19.5M | €4.9M |
| Fee and Commission Expense | €43.8M | €40.7M |
| Gains Losses On Change In Fair Value Estimates of Biological Assets For Current Period | €40.6M | €37.4M |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | €9.0M | €35.9M |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €66.2M | €23.5M |
| Income Taxes Paid Refund Classified As Operating Activities | €295.0M | €219.6M |
| Increase Decrease In Cash and Cash Equivalents | -€11.7M | €117.6M |
| Increase Decrease In Working Capital | €44.2M | €173.5M |
| Increase Decrease Through Sharebased Payment Transactions | €3.8M | €1.2M |
| Interest Expense | €143.5M | €113.1M |
| Interest Paid Classified As Financing Activities | €136.4M | €110.0M |
| Investment Accounted For Using Equity Method | €210.6M | €211.7M |
| Licences and Franchises | €1.23B | €1.21B |
| Miscellaneous Other Operating Expense | €845.4M | €696.5M |
| Other Adjustments To Reconcile Profit Loss | €80.1M | €28.2M |
| Other Comprehensive Income | €65.8M | -€46.9M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | €65.8M | -€41.1M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €0 | -€5.8M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | €65.8M | -€41.1M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €0 | -€5.8M |
| Other Current Financial Assets | €7.4M | €19.9M |
| Other Current Financial Liabilities | €8.1M | €6.3M |
| Other Current Liabilities | €348.5M | €293.9M |
| Other Current Receivables | €255.9M | €253.7M |
| Other Finance Income Cost | €7.6M | -€5.1M |
| Other Intangible Assets | €28.4M | €32.5M |
| Other Noncurrent Assets | €1.2M | €600.0K |
| Other Noncurrent Financial Assets | €2.8M | €2.7M |
| Other Noncurrent Liabilities | €7.1M | €6.6M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €20.2M | €7.9M |
| Purchase of Financial Instruments Classified As Investing Activities | €2.5M | €43.9M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €374.2M | €396.3M |
| Revenue and Operating Income | €5.60B | €5.51B |
| Revenue From Contracts With Customers | €5.57B | €5.48B |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €29.5M | €28.4M |
| Trade and Other Current Payables To Trade Suppliers | €517.9M | €560.7M |
Methodology
Every line item above is a fact tagged in MOWI ASA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.